BMS completes Amylin Pharmaceuticals acquisition
05:43 EDT 9 Aug 2012 | Avakado
Bristol-Myers Squibb Company has completed the tender offer through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc at a purchase price of $31.00 per share. As..
Original Article: BMS completes Amylin Pharmaceuticals acquisition
More From BioPortfolio on "BMS completes Amylin Pharmaceuticals acquisition"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
